Rheumatoid Arthritis

Latest News


Direct Costs to Patients for RA Treatment:  $12,509-$36,053

The annual direct costs for rheumatoid arthritis (RA) patients are estimated to range from $12,509-$36,053. A late diagnosis costs even more and one in 10 new RA cases are usually diagnosed late. In this presentation, Kathryn Johnson, RPh, of CVS Health breaks down the numbers.

ACR Set to Issue Updated RA Treatment Guidelines

The American College of Rheumatology is expected to issue updated treatment guidelines for rheumatoid arthritis no later than spring 2021. The new guidelines will include recommended uses for biologics approved since the last update in 2015―including JAK inhibitors.

ACR Conference Roundup:  New RA Treatment Guidelines Preview

In this week's news roundup from Rheumatology Network, we highlight studies presented at the annual meeting of the American College of Rheumatology, which wrapped this week. Among the stories we covered included a preview of the soon-to-be released rheumatoid arthritis guidelines, promising new treatments for lupus nephritis and advances in osteoporosis care. Learn more in today's news roundup.

Q&A: Methotrexate and Tuberculosis

Tuberculosis screening and ongoing clinical care is needed for patients prescribed methotrexate, particularly if co-administered with corticosteroids or other immunosuppressants, who live in areas where tuberculosis is common, according to researchers recently reporting at the annual meeting of the American College of Rheumatology.

Tofacitinib, Adalimumab, Methotrexate Show Similar Influenza Adverse Events in RA

In a study that examined the influenza adverse events (AEs) of tofacitinib (Xeljanz, Pfizer) in patients with rheumatoid arthritis, similar AEs were seen with tofacitinib, adalimumab, methotrexate, and placebo, and between different tofacitinib doses and patient age groups, according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.

In a study presented at the annual meeting of the American College of Rheumatology, UK researchers showcase a study in which artificial intelligence was successfully used to identify ACPA positivity and CRP of greater than 12.3 mg/L to identify rheumatoid arthritis patients more likely to respond to sarilumab.

minorities rheumatic disease acr annual meeting

In a study that explored the longitudinal racial disparities in rheumatoid arthritis treatment and emergency department use, black rheumatoid arthritis patients were found to be less likely to receive biologics and instead, be given a prescription for glucocorticoids, say researchers reporting at the annual meeting of the American College of Rheumatology on Friday.

Rheumatic Disease Research Driven by Smartwatch Data

Rheumatoid arthritis patients overwhelmingly embraced the idea of collecting patient reported outcomes by smartwatch, shows a study due to be presented on Monday in a presentation to be given at the American College of Rheumatology annual meeting.

Rheumatoid Arthritis With PTSD, Anxiety and Depression

Stress and anxiety can wreak havoc on one's health and hinder recovery, particularly for patients with chronic conditions, such as rheumatoid arthritis. In an article published online Sept. 13 in ACR Open Rheumatology, Joshua F. Baker, M.D., and colleagues report the results of study that finds veterans with rheumatoid arthritis and comorbid PTSD, depression, or anxiety, have poor persistence of methotrexate and TNFi therapies leading to worse outcomes. He addresses the study findings in this interview.

early rheumatoid arthritis diagnosis

In order to achieve the best clinical outcomes in rheumatoid arthritis, experts suggest an early diagnosis is essential. Early and prompt treatment is recommended to reduce the risk of permanent joint damage. In this quiz, we test your knowledge about an early rheumatoid arthritis diagnosis.

Rheumatoid Arthritis As Two Diseases

The underlying pathogenesis of rheumatoid arthritis with and without autoantibodies may be different. Researchers say that "it is time to formally subdivide RA into type 1 (with autoantibodies) and type 2 (without autoantibodies)."

One-on-one With Dr. Dimitrios Pappas:  Etanercept as Monotherap

In today’s one-on-one interview, we talk with Dimitrios A. Pappas, M.D., MPH, scientific director of the Corrona RA Registry and an adjunct professor with Columbia University. He and his team recently published results from the registry in ACR Open Rheumatology which show that rheumatoid arthritis patients may be able to maintain remission or low disease activity with etanercept (Enbrel, Amgen) monotherapy long-term treatment.